Q&A With Anne Cross from Washington University School of Medicine: Additional Treatments Could Provide Benefit to Patients With Multiple Sclerosis

Video

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

Anne H. Cross from the Washington University School of Medicine discussed this potential new treatment during the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers in Indianapolis. Cross said that while these treatments have not been approved for patients with the relapsing form of the condition. She also added that if they are approved it will be important that only properly trained healthcare professionals provide them to patients.

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
Pediatric Hidradenitis Suppurativa Severity not Linked to Obesity
Rizankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.